- Research, Innovation and Commercialisation - Research Publications
Research, Innovation and Commercialisation - Research Publications
Permanent URI for this collection
2 results
Filters
Reset filtersSettings
Statistics
Citations
Search Results
Now showing
1 - 2 of 2
-
ItemSOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naive CD8 T cells, limiting their autoimmune potentialDavey, GM ; Starr, R ; Cornish, AL ; Burghardt, JT ; Alexander, WS ; Carbone, FR ; Surh, CD ; Heath, WR (ROCKEFELLER UNIV PRESS, 2005-10-17)Mice that are deficient in suppressor of cytokine signaling-1 (SOCS-1) succumb to neonatal mortality that is associated with extensive cellular infiltration of many tissues. T cells seem to be necessary for disease, which can be alleviated largely by neutralizing interferon-gamma. Examining T cell receptor (TCR) specificity shows that even monospecific T cells can mediate disease in SOCS-1-deficient mice, although disease onset is substantially faster with a polyclonal T cell repertoire. A major phenotype of SOCS-1-/- mice is the accumulation of CD44(high)CD8+ peripheral T cells. We show that SOCS-1-deficient CD8, but not CD4, T cells proliferate when transferred into normal (T cell-sufficient) mice, and that this is dependent on two signals: interleukin (IL)-15 and self-ligands that are usually only capable of stimulating homeostatic expansion in T cell-deficient mice. Our findings reveal that SOCS-1 normally down-regulates the capacity of IL-15 to drive activation and proliferation of naive CD8 T cells receiving TCR survival signals from self-ligands. We show that such dysregulated proliferation impairs the deletion of a highly autoreactive subset of CD8 T cells, and increases their potential for autoimmunity. Therefore, impaired deletion of highly autoreactive CD8 T cells, together with uncontrolled activation of naive CD8 T cells by homeostatic survival ligands, may provide a basis for the T cell-mediated disease of SOCS-1-/- mice.
-
ItemCD8+ T Cells from a Novel T Cell Receptor Transgenic Mouse Induce Liver-Stage Immunity That Can Be Boosted by Blood-Stage Infection in Rodent MalariaLau, LS ; Fernandez-Ruiz, D ; Mollard, V ; Sturm, A ; Neller, MA ; Cozijnsen, A ; Gregory, JL ; Davey, GM ; Jones, CM ; Lin, Y-H ; Haque, A ; Engwerda, CR ; Nie, CQ ; Hansen, DS ; Murphy, KM ; Papenfuss, AT ; Miles, JJ ; Burrows, SR ; de Koning-Ward, T ; McFadden, GI ; Carbone, FR ; Crabb, BS ; Heath, WR ; Mota, MM (PUBLIC LIBRARY SCIENCE, 2014-05)To follow the fate of CD8+ T cells responsive to Plasmodium berghei ANKA (PbA) infection, we generated an MHC I-restricted TCR transgenic mouse line against this pathogen. T cells from this line, termed PbT-I T cells, were able to respond to blood-stage infection by PbA and two other rodent malaria species, P. yoelii XNL and P. chabaudi AS. These PbT-I T cells were also able to respond to sporozoites and to protect mice from liver-stage infection. Examination of the requirements for priming after intravenous administration of irradiated sporozoites, an effective vaccination approach, showed that the spleen rather than the liver was the main site of priming and that responses depended on CD8α+ dendritic cells. Importantly, sequential exposure to irradiated sporozoites followed two days later by blood-stage infection led to augmented PbT-I T cell expansion. These findings indicate that PbT-I T cells are a highly versatile tool for studying multiple stages and species of rodent malaria and suggest that cross-stage reactive CD8+ T cells may be utilized in liver-stage vaccine design to enable boosting by blood-stage infections.